ArticleCureus2025
Empagliflozin Perception Mapping Survey.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHeart failure (HF) is a frequent yet often underdiagnosed comorbidity among individuals with type 2 diabetes mellitus (T2DM). Sodium-glucose cotransporter-2 (SGLT2) inhibitors, particularly empagliflozin, are known to provide significant cardiovascular and renal benefits and are endorsed by international guidelines. However, real-world gaps in adoption persist, influenced by diagnostic challenges, cost considerations, and clinician familiarity. This survey assessed physician perceptions and prescribing practices regarding empagliflozin across diverse T2DM patient profiles in India.
methodsA cross-sectional, questionnaire-based survey was conducted using a voluntary convenience sampling approach among physicians from various specialities managing T2DM. As the study involved anonymized physician responses without patient-level data, ethical approval was not applicable. The survey captured information on demographic characteristics, heart failure risk assessment, SGLT2 inhibitor prescribing patterns, perceived cardio-renal benefits, and perceived barriers. Data were analyzed descriptively and summarized as frequencies and proportions.
resultsMost respondents acknowledged that HF remains underdiagnosed in T2DM and recognized the role of empagliflozin in patients with cardiovascular and renal comorbidities. Physicians reported frequent use of empagliflozin in T2DM with multiple cardiovascular risk factors, established atherosclerotic cardiovascular disease (ASCVD), and chronic kidney disease (CKD). Recent evidence supporting its benefit in both, heart failure with reduced ejection fraction (HFrEF) and heart failure with preserved ejection fraction (HFpEF) was reflected in prescribing trends. Cost, guideline awareness, and therapeutic inertia were cited as continuing barriers to optimal utilization.
conclusionsIndian physicians demonstrate strong awareness and largely guideline-concordant prescribing attitudes toward empagliflozin in T2DM with cardiovascular or renal complications. Nevertheless, under-recognition of asymptomatic HF and variability in CKD management highlight the need for targeted education and policy initiatives to further strengthen evidence-based practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.